A case of paclitaxel-induced maculopathy treated with methazolamide.
A 54-year-old female patient who had been undergoing anti-cancer chemotherapy and radiotherapy for seven years after surgery for left breast cancer visited our clinic for visual disturbance in the right eye at nine months after paclitaxel administration. The best-corrected visual acuity was 0.5 in the right eye and 1.0 in the left eye. The patient was diagnosed with maculopathy due to paclitaxel administration based on the finding of cystoid macular edema in the right eye on fundus examination and optical coherence tomography; however, no leakage was detected on fluorescein angiography. Thus, drug replacement was planned. On the other hand, no abnormal finding was observed in the left eye. However, as the anti-cancer effect of paclitaxel is significant, replacing paclitaxel with another agent was not warranted; therefore, maintenance therapy with methazolamide was performed before and after administering the anti-cancer agent. Aggravation of cystoid macular edema was prevented, and vision improvement was achieved by oral maintenance therapy with methazolamide. In addition, the same fundus findings as shown in the right eye were detected in the left eye at 16 months after paclitaxel administration. After administering methazolamide, macular thickness was reduced, and vision was improved in the left eye. Paclitaxel administration was discontinued due to cutaneous metastasis from the breast cancer, and another anti-cancer agent was then administered. No subsequent cystoid macular edema has occurred.
Department of Ophthalmology, Dongkang Hospital, Ulsan, Korea.
Nam Kyun
NK
Koo
Yu Cheol
YC
Kim
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D004232:Diuretics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008269:Macular Edema / Q000139:chemically induced* / Q000188:drug therapy*; D008704:Methazolamide / Q000627:therapeutic use*; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects*; D014792:Visual Acuity
D000972:Antineoplastic Agents, Phytogenic; D004232:Diuretics; D017239:Paclitaxel; D008704:Methazolamide